""Based on the significant unmet need in Alzheimer's disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutide's potential, despite a low likelihood of success. "While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities," he said."
"The patients who took part in the Evoke trials were aged between 55 and 85 and had mild cognitive impairment or mild dementia due to Alzheimer's disease. Dementia progression was monitored and measured through tests and interviews. Treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers, but this did not translate into delaying progression of the disease."
Semaglutide, the active ingredient in Wegovy, did not slow the progression of Alzheimer's disease in two large trials involving more than 3,800 participants. Participants were aged 55 to 85 and had mild cognitive impairment or mild dementia due to Alzheimer's disease. Dementia progression was monitored through tests and interviews. Treatment improved Alzheimer's-related biomarkers but did not delay clinical disease progression compared with placebo. The results are to be presented at an Alzheimer's conference and are not yet peer-reviewed. Semaglutide continues to provide benefits for people with type 2 diabetes, obesity, and related comorbidities. Alzheimer's involves multiple biological processes, so no single approach is likely to be sufficient.
Read at www.bbc.com
Unable to calculate read time
Collection
[
|
...
]